- **Article type:** Original Research
- **Title:** Predicting skin cancer risk from facial images with an explainable artificial intelligence
- (XAI) based approach: a proof-of-concept study
- 4 **Authors:** X. Liu^{*1,2}, T.E. Sangers^{*3}, T. Nijsten³, M. Kayser⁴, LM. Pardo³, E.B. Wolvius², G.V.
- 5 Roshchupkin^{#1,5}, M. Wakkee^{#3}
-
- *These authors contributed equally to this work.
- #These authors contributed equally to this work.
- $\begin{array}{c} 8 \\ 9 \\ 10 \end{array}$ ¹ Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center
- Rotterdam, Rotterdam, the Netherlands
- ² Department of Oral & Maxillofacial Surgery, Erasmus MC University Medical Center
- Rotterdam, Rotterdam, the Netherlands
- ³ Department of Dermatology, Erasmus MC Cancer Institute, Erasmus MC University Medical
- Center Rotterdam, Rotterdam, the Netherlands
- ⁴ Department of Genetic Identification, Erasmus MC University Medical Center Rotterdam,
- Rotterdam, the Netherlands
- ⁵ Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam,
- the Netherlands
-

Corresponding author:

- Marlies Wakkee, MD PhD
- Dr. Molewaterplein 40, 3015 GD Rotterdam
- m.wakkee@erasmusmc.nl
-

 Funding sources: The Rotterdam Study is funded through unrestricted research grants from Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the

- Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly
- (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and
- Sports, the European Commission (DG XII), and the Municipality of Rotterdam. G.V.
- Roshchupkin is supported by the ZonMw Veni grant (Veni, 549 1936320).
-
- **Conflicts of Interest**: The authors declare the following financial interests which may be considered potential competing interests: The Erasmus MC Department of Dermatology has received an unrestricted research grant from SkinVision B.V
-

 IRB approval status: The Rotterdam Study has been approved by the Erasmus MC Medical Ethical Committee (MEC-02-1015), and by the Dutch Ministry of Health, Welfare and Sport

- (Population Screening Act, reference 3295110-1021635-PG).
-
-
-
-

Abstract

Background:

 Efficient identification of individuals at high risk of skin cancer is crucial for implementing personalized screening strategies and subsequent care. While Artificial Intelligence holds promising potential for predictive analysis using image data, its application for skin cancer risk prediction utilizing facial images remains unexplored. We present a neural network-based explainable artificial intelligence (XAI) approach for skin cancer risk prediction based on 2D facial images and compare its efficacy to 18 established skin cancer risk factors using data from the Rotterdam Study.

Methods:

 The study employed data from the Rotterdam population-based study in which both skin cancer risk factors and 2D facial images and the occurrence of skin cancer were collected from 2010 to 2018. We conducted a deep-learning survival analysis based on 2D facial images using our developed XAI approach. We subsequently compared these results with survival analysis based on skin cancer risk factors using cox proportional hazard regression.

Findings:

 Among the 2,810 participants (mean Age=68.5±9.3 years, average Follow-up=5.0 years), 228 participants were diagnosed with skin cancer after photo acquisition. Our XAI approach achieved superior predictive accuracy based on 2D facial images (c-index=0.72, SD=0.05), outperforming that of the known risk factors (c-index=0.59, SD=0.03).

Interpretation:

 This proof-of-concept study underscores the high potential of harnessing facial images and a tailored XAI approach as an easily accessible alternative over known risk factors for identifying individuals at high risk of skin cancer.

Funding:

The Rotterdam Study is funded through unrestricted research grants from Erasmus Medical Center

and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and

Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of

Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European

Commission (DG XII), and the Municipality of Rotterdam. G.V. Roshchupkin is supported by the

ZonMw Veni grant (Veni, 549 1936320).

Research in context

Evidence before this study

We searched PubMed for articles published in English between Jan 1, 2000, and Sept 28, 2023,

82 using the search terms "skin cancer" AND "artificial intelligence" OR "deep learning". Our

search returned more than 1,323 articles. We found no study had explored the feasibility of

predicting the risk of developing skin cancer based on facial images that were taken before the

first diagnosis of skin cancer. Although there were studies focused on deep learning image

analysis and skin cancer, those are based on skin cancer lesion images. We found current skin

cancer risk prediction models are still hampered by dependencies on complex patient data,

including genetic information, or rely on self-reported patient data.

Added value of this study

In this study, we presented a neural network-based explainable artificial intelligence (XAI)

approach for skin cancer risk prediction based on 2D facial images. To the best of our

knowledge, our study is the first to utilize facial images as predictors in a skin cancer survival

analysis. Our novel image-based approach showed superior performance when juxtaposed with

traditional methods that relied on clinical and genetic skin cancer risk factors, as observed within

our study population

Implications of all the available evidence.

 This proof-of-concept study underscores the high potential of harnessing facial images and a tailored XAI approach as an easily accessible alternative over known risk factors for identifying individuals at high risk of skin cancer.

Introduction

 Skin cancer, the most common form of cancer in individuals of European ancestry with lighter skin tones, presents a significant public health concern. The two most common types of skin cancer, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), together referred to as 106 keratinocyte carcinoma (KC), account for [an estimated 6 million](https://onlinelibrary.wiley.com/doi/10.1002/cam4.4046)¹ new cases each year across the globe. BCC, the most prevalent variant, grows slowly, often appearing as nodular, pigmented, or waxy lesions on sun-exposed skin. SCC, though less common than BCC, is more aggressive and usually presents as a scaly or erythematous patch or nodule. Even less common, but far more 110 lethal, is malignant melanoma, which causes an estimated [57,000 deaths globally each year.](https://jamanetwork.com/journals/jamadermatology/fullarticle/2790344)² Due to longer life expectancies and past excessive UV exposure, the number of KC and melanoma cases has surged over recent decades, and [this trend is anticipated to continue.](https://jamanetwork.com/journals/jamadermatology/fullarticle/2790344) 2

 [Early diagnosis of skin cancer can mitigate morbidity and mortality by preventing the](https://jamanetwork.com/journals/jama/fullarticle/192984) [progression to late-stage disease.](https://jamanetwork.com/journals/jama/fullarticle/192984)³ However, population-wide screening programs have not been 115 proven cost-effective,⁴ or convincingly demonstrated a reduction in skin cancer-related mortality or morbidity. However, [personalized screening programs for individuals at high risk of developing](https://pubmed.ncbi.nlm.nih.gov/27458949/) [skin cancer](https://pubmed.ncbi.nlm.nih.gov/27458949/)⁵ are considered as a potentially more feasible strategy to combat the ongoing skin 118 cancer epidemic.⁶ Although accurate stratification of individuals at increased risk of developing skin cancer is essential for targeted screening, it remains a challenge to develop tools with sufficient predictive performance that are suitable for wide-scale use. [Many](https://www.nature.com/articles/s41467-020-20246-5) [existing](https://pubmed.ncbi.nlm.nih.gov/31520533/) [prediction](https://jamanetwork.com/journals/jamadermatology/fullarticle/2749356&sa=D&source=docs&ust=1666006574966825&usg=AOvVaw2Qslq5Zqn48jFD5NwugrZi)^{7,8,9} models are hampered by dependencies on complex patient data, including genetic information, or rely on self-reported patient data, thereby making them susceptible to recall bias and social-123 desirability bias.

 [Artificial intelligence \(AI\), specifically convolutional neural networks \(CNNs\), have](https://pubmed.ncbi.nlm.nih.gov/28117445/) [demonstrated high accuracy in detecting skin cancer from skin lesion images in recent years.](https://pubmed.ncbi.nlm.nih.gov/28117445/)¹¹ Yet, their potential in stratifying individuals based on skin cancer risk remains largely uncharted due to the scarcity of longitudinal datasets. One potential direction for such screening strategies involves the use of personal facial images. These images could reveal key risk factors associated with skin cancer, such as age, skin color, and signs of UV damage. Furthermore, capturing facial images requires minimal effort (such as taking a selfie with a smartphone) and is not affected by recall bias thus offering a potentially easily accessible tool for identifying high risk individuals in the general population.

Here, we develop a neural network-based explainable artificial intelligence $(XAI)^{36,37}$ approach that predicts skin cancer risk from 2D-facial images and utilize population-based data from the Rotterdam Study (RS) to demonstrate its performance. To assess its effectiveness, we compared the performance of our novel image-based approach with traditional clinical and genetic skin cancer risk factors in RS.

Methods

Study design and participants

 [The RS is an ongoing large prospective population-based cohort study in Ommoord, a region in](https://pubmed.ncbi.nlm.nih.gov/32367290/) [Rotterdam, the Netherlands.](https://pubmed.ncbi.nlm.nih.gov/32367290/)¹² Since January 1990, the RS has been enrolling individuals aged 50 and over from the general population. Participants undergo comprehensive baseline examinations and visit a dedicated study center every 3-4 years. During these visits they also undergo a full-body skin examination (FBSE) performed by a dermatology-trained physician which also focuses on detecting skin (pre-)malignancies and skin cancer. As of 2010, standardized full facial images are taken of participants using a Premier 3dMD face3-plus UHD camera (3dMD Inc., Atlanta, GA, USA).

Skin cancer and risk factor measurements

 Skin cancer diagnoses, both prior to and after the facial photo was taken, along with their respective body locations, were collected for all RS participants by linkage to the [Dutch nationwide network](https://pubmed.ncbi.nlm.nih.gov/17429138/) 153 and registry of histo- [and cytopathology \(PALGA\).](https://pubmed.ncbi.nlm.nih.gov/17429138/)¹³ Skin cancer-related risk factors were collected through a combination of home interviews and study center visits. Available skin cancer determinants included sex, age, skin color, hair color, eye color, pigment status [\(combined](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496285/) [variable](https://pubmed.ncbi.nlm.nih.gov/26121210/)^{14,15} hair and eye color), number of naevi, baldness in men, body mass index (BMI), socioeconomic status, history of living in a sunny country, tendency to develop sunburn, alcohol intake, coffee consumption, smoking, Glogau wrinkle classification, and a genetic risk score (GRS) for KC as well as melanoma utilizing single-nucleotide polymorphisms (SNPs) that are significantly associated with these specific types of skin cancer.^{34,35}

Case definition

 Events were defined as participants, who received their first diagnosis of skin cancer (BCC, SCC or melanoma) after the date of the facial images being taken. To ensure the exclusion of participants who already had a skin cancer diagnosis at the time of the photograph (i.e., *left-censored* samples), individuals with a confirmed histopathological skin cancer diagnosis prior to their photograph or within 30 days after the FBSE were excluded from the study. Follow-up of all participants ended 168 at the time of death, or the date of censoring on July $1st$, 2018, whichever came first. Death was ascertained through linking with the municipal register. *Right-censored* samples were defined as participants, who had not received a diagnosis of skin cancer by the date of censoring (July 1st, 2018), or who died before the date of censoring.

Facial image acquisition and preprocessing

 Facial images of the RS participants were taken using a 3dMDface system (3dMD Inc., Atlanta, GA, USA) photogrammetric device by medical doctors, who were specifically trained in operating the device. The system comprised a central modular camera unit, flanked by two additional side units, and underwent daily calibration. Image acquisition took place in a designated 3D imaging room with consistent ambient lighting. An adjustable chair was used in a fixed position, to ensure a standard level of height and fixed distance between subjects and the camera system. Participants were requested to remove glasses and to wear a hair band to prevent hair from obscuring the forehead or ears. During the image capture process, participants faced the central modular camera unit maintaining a neutral facial expression with their eyes open. Frontal 2D facial images were automatically derived from the 3dMD software.

184 For the detection of facial landmarks, we utilized $Dlib$, ¹⁶ a facial image processing library. The detected facial landmarks were subsequently employed to crop and align the facial regions, as illustrated in Figure S8. To exclude the neck or shoulder regions from the images, those areas were masked as black pixels. Additionally, histogram equalization was applied to enhance the visual quality of each facial image as well as to mitigate potential lighting variations. The final resolution employed for our analysis was set to 224x224 pixels.

Deep learning analysis

AI-based endophenotypes derived from facial images

 An autoencoder is an artificial neural network architecture employed for learning compressed representations of input data in a self-supervised manner, meaning that it does not require patient- specific information during the training process. The autoencoder consists of an encoder and a decoder, which collectively enable non-linear feature mapping. The encoder is responsible for compressing high-dimensional facial images into low-dimensional latent features, while the decoder reconstructs facial images from these latent features.

199 $Z = \text{Encode}(F)$

200 $F' = Decode(Z)$

201 where $Z = [Z_0, Z_1, ..., Z_N]$ denotes the N latent features, Encode() and Decode() functions correspond to the down-sampling and up-sampling processes F denotes the input 2D facial image, while F′ represents the reconstructed 2D facial image.

204 For our analysis, we used a deep convolutional autoencoder¹⁷ (detailed architecture in Figure S3c) consisting of four encoder layers and four decoder layers to derive low-dimensional representations, which we further defined as facial endophenotypes. To make the trade-off between reconstruction error and dimensional complexity, we conducted experiments with varying numbers of

 endophenotypes. The optimum number was found to be 200. The derived facial endophenotypes were further used as predictors in the survival analysis.

Explainable AI (XAI) techniques

 By selectively decoding a subset of endophenotype(s), we are able to generate a sequence of facial images showing changes in facial features corresponding to the changes of selected endophenotype(s). Implementation details about the selectively decoding can be found in Figure S5a (in supplementary).

Cox proportional hazard regression (CPH) analysis

218 We performed a survival analysis employing cox proportional hazard regression $(CPH)¹⁸$ to predict the risk of participants developing skin cancer over time. Predictors included either the 18 risk factors or the 200 facial endophenotypes. Additionally, time-to-event (TTE) was included as an essential predictor in the model training. For events, TTE was calculated as the interval between the date of the first diagnosis of skin cancer and the date when the facial image was taken; In the case of right-censored samples, TTE was calculated as the interval between the date of censoring (or death) and the date when a facial image was taken.

Deep cox proportional hazards regression (DCPH) analysis

 A deep cox proportional hazard regression (DCPH) model is an extension of the linear cox proportional hazards (CPH) model. Compared to DPH, DCPH enables non-linear modeling of the predictors, and thus it is able to model more complex relationships between predictors and the

230 \cdot risk.¹⁹ The parameters of the DCPH model are optimized by minimizing the following log-partial 231 likelihood cost function which is widely used in survival analysis models: $20,21,22$

$$
Loss = -\sum_{i \in E} (h(x_i) - ln \sum_{j \in R} e^{h(x_j)})
$$

233 where E represents the set of events and R denotes the set of right-censored samples, and the TTE 234 for individual j is greater than the TTE for individual i, x_i and x_j represent the predictors for 235 individuals i and j, and $h(x)$ and $h(x_i)$ represent the network predictions for individuals i and j.

236 The DCPH model consisted of two fully connected layers and one neuron in the output layer.

237 Detailed architectures of the DCPH model can be found in Supplementary Figure S3b.

238

239 *Deep Convolutional cox proportional hazards regression analysis (DCCPH)*

240 Integrating 2D convolutional neural networks²³ with the cost function of DCPH, we can utilize the entire facial image as input and directly compute a skin cancer risk score for each participant. This integrated model was referred to as the deep convolutional cox proportional hazard (DCCPH) model, which consisted of four convolutional layers, two fully connected layers and one neuron in the output layer. Detailed architectures of the DCCPH model can be found in Supplementary Figure S3c.

246

247 **Survival analysis and experiment settings**

 In all experiments of the survival analysis, left-censored samples (i.e., participants diagnosed with skin cancer prior to the facial image being taken) were excluded. We utilized three models in the survival analysis: CPH, DCPH, and DCCPH. For both the CPH and DCPH models, we explored three types of predictors: 1) age alone, 2) 18 known risk factors, and 3) facial endophenotypes. In

 the DCCPH model, we employed 2D facial images without extracting facial endophenotypes as predictors.

 All the three models estimate the risk over time, but we only provide the risk score at a single time point, which is at the end of the study. To evaluate the predictive performance of the models, we calculated the concordance-index (c-index) using the following equation:

257

$$
C = \frac{\sum_{i \neq j} 1(r_i < r_j) 1(T_i > T_j) \delta_j}{\sum_{i \neq j} 1(T_i > T_j) \delta_j}
$$

258 where δ_i is a variable that is assigned a value of 1, if individual j is an event and 0 if individual j is

a right-censored sample, T is the TTE for an individual and r is the risk score for an individual.

 A c-index of 0.5 indicates a random prediction, while a c-index of 1 indicates a perfect prediction. In all prediction experiments, we employed a consistent practice of splitting the samples into a training set and a test set, with an 80:20% ratio. We repeated this split 20 times with random permutations and calculated the mean and standard deviation of the c-index.

 We performed an additional analysis where we stratified the right-censored samples into different subgroups based on their follow-up years. It is important to note that patient information in this study was not updated beyond July 1st, 2018. Consequently, some right-censored samples had a relatively short follow-up period and may have been diagnosed with skin cancer shortly after that date. These right-censored samples with a shorter follow-up time could be deemed less reliable compared to those with longer follow-up periods. In consequence, including right-censored samples with short follow-up years in the analysis could potentially impact the prediction model negatively. Therefore, we stratified the right-censored samples into 5 subgroups based on the follow-up years, while ensuring age matching among the subgroups. The subgroups were defined 273 as follows: 1) > 2 follow-up years (N=1139); 2) > 3 follow-up years (N=1129); 3) > 4 follow-up 274 years (N=840); 4) > 5 follow-up years (N=548); 5) > 6 follow-up years (N=535), The event group

²⁸⁶ **Results**

288

287 **Study population and risk factors**

 We included a total of 3,371 participants from the RS cohort, who had a 2D-facial image and underwent assessment for skin cancer risk factors. Among them, 23.4% (n=789) were diagnosed with skin cancer, of which 71.1% (n=561, *left-censored* participants) were diagnosed prior to the facial image being taken, and 28.9% were diagnosed afterwards (n=228, *events*). Figure S7 shows the histogram distribution of time-to-event (TTE) of these 228 events, with an average TTE of 971 days (SD 678 days). Among these 228 events, 163 had a BCC, 68 had an SCC and 11 had a melanoma. Left-censored participants were excluded from the survival analysis. Table 1 shows the 296 distribution of the 18 potential skin cancer risk factors among the study population $(N=2.810)$, of which the median age was 67.1 years (IQR 14.1 years) and 57.4% were women. We examined the association between known skin cancer risk factors and the facial endophenotypes we derived from the facial images (Figure S4), and visually represented the identified associations on the face (Figure S5) via XAI techniques.

301

304 Right-censored samples: Never had skin cancer before the end of the study;
305 Events: Diagnosed with skin cancer at least 30 days after the facial photo was

Events: Diagnosed with skin cancer at least 30 days after the facial photo was taken;

306 FBSE: Full-body skin examination;

307 GRS_KC: Polygenetic risk score for KC;

308 GRS_MM: Polygenetic risk score for melanoma

309 Risk factors were imputed. Table S1 shows the characteristics of non-imputed risk factors.

310

311 **Skin cancer risk prediction in survival analysis**

312

313 Table 2 shows the c-index values for different prediction models using various predictors as input.

314 In the risk factor analysis, the age-only analysis yielded a c-index of about 0.55, which increased

315 to 0.59 when all other known risk factors were included. However, the analysis of facial

316 endophenotypes resulted in higher c-index values of 0.72, which remained similar at 0.71 when

317 using the facial images without extracting the facial endophenotypes. Comparing the prediction

318 models, the CPH showed better performance when using risk factors as input, while the DCPH

319 was more effective when employing facial endophenotypes as input.

- 320 In our main analysis, we focused on skin cancer occurring at any location on the body. We further
- 321 stratified the event group into two subgroups: skin cancer on the face and skin cancer on other
- 322 parts of the body excluding the face. Interestingly, we observed similar patterns and trends in the
- 323 analysis across different stratifications based on the location of skin cancer.
- 324
- 325 Table 2: C-index (mean/SD) of skin cancer risk prediction in survival analysis.

- 326 CPH: Cox proportional hazard regression
- 327 DCPH: Deep Cox proportional hazard regression
- 328 DCCPH: Deep convolutional cox proportional hazards regression
- 329 Only Right-censored samples (N= 535) with > 6 follow-years were included.
- 330 Results were based on imputed risk factors. Table S2 shows the results based on non-imputed risk factors. 331
-

332 **Facial endophenotypes association with known risk factors**

- 333 Figure 1 shows the associations between traditional skin cancer risk factors and statistically
- 334 significant facial endophenotypes identified in the survival analysis (CPH facial endophenotypes)
- 335 in Table 2. Combining the effects of 12 statistically significant facial endophenotypes, several key

 patterns emerged. Strong associations of facial endophenotypes were observed with age (positive), Glogau wrinkle classification (positive), history of living in a sunny country (positive), BMI (negative), and hair color and pigment status (higher risk in lighter color). Weaker associations were found with sex (higher risk in males), tendency to develop sunburn (negative) and skin color (higher risk with lighter skin color). No significant associations were detected with alcohol consumption, coffee consumption, smoking, eye color, social economic status, number of naevi, baldness and genetic risk score.

344
345

Figure 1. Statistically significant facial endophenotypes in survival analysis are associated with known risk factors,

346 in the analysis of skin cancer on any location of the body. The x-axis represents the different risk factors, while the

347 y-axis represents the index of facial endophenotypes that exhibited statistical significance in the survival analysis.
348 The "sum" row represents the summation of each row. The values of associations are normalized f

The "sum" row represents the summation of each row. The values of associations are normalized from -1 to 1 for

- 349 each column, where red indicates a positive association, indicating a higher risk of skin cancer associated with
350 higher values of the corresponding risk factor, such as age. higher values of the corresponding risk factor, such as age.
- 351
- 352

Explainable AI (XAI)

 In order to gain insights into the facial features contributing to skin cancer prediction, we selectively decoded the statistically significant facial endophenotypes identified in the survival analysis (CPH facial endophenotypes) and generated a sequence of facial images representing low to high risk of skin cancer via XAI techniques (implementation details in Figure S5a). Figure 2 presents synthesized facial images that the prediction model considered as having low to high risk of skin cancer, stratified based on whether the cancer occurred on the face, on other body parts excluding the face, or anywhere on the body including the face. The result indicates that factors such as a lower BMI or increased facial erythema might be linked to a higher risk. Notably, participants in the sub-group of skin cancer occurring outside the face had never been diagnosed with skin cancer on the face before the date of censoring.

Skin cancer on any location

 body locations excluding the face, as well as anywhere on the body including the face. The synthetic faces shown in the figure were reconstructed via selectively decoding statistically significant facial endophenotypes in the survival analysis (CPH facial endophenotypes) in Table 2.

In-depth analysis of TTE in survival analysis

 The relationship between the skin cancer prediction score and TTE of events during the test stage of the survival analysis (CPH and DCPH facial endophenotypes) is illustrated in Figure 3. Notably, the TTE information of each participant was not included into the model as a predictor in the test stage. The plot reveals that events with a higher prediction score, indicating a higher risk of skin cancer, tend to have a shorter TTE. A shorter TTE implies that participants were diagnosed with skin cancer earlier after the facial images were taken, suggesting that their faces may have exhibited early signs of skin cancer at the time the photo was made. The CPH and DCPH models effectively identified these participants, assigning them to overall higher risk scores compared to subjects with a longer TTE. This effect, although to a lesser extent, was also observed for participants with skin cancer on other parts of the body excluding the face (Figure S9).

386 Figure 3: Relationship between risk prediction score and time to event (TTE) for N=44 events in the test set. a)
387 Analysis of (CPH facial endophenotypes) and b) Analysis of (DCPH facial endophenotypes) for skin canc Analysis of (CPH facial endophenotypes) and b) Analysis of (DCPH facial endophenotypes) for skin cancer at any location on the body. The X-axis represents the TTE in days, while the Y-axis represents the prediction risk score normalized to a range of 0 to 1. A higher predicted score indicates a higher risk of skin cancer.

384
385

 Figure 4 shows the survival analysis results with the stratification of right-censored samples based on their follow-up years. Age was matched between the event group and right-censored subgroups, so the c-index curve of (CPH age) served as a baseline. It is evident that compared to (CPH age), the results of (CPH 18 known risk factors), (CPH facial endophenotypes) and (DCPH facial endophenotypes) showed a trend of increasing c-index in subgroups with longer follow-up years.

397

398 Figure 4: Stratification of right-censored samples based on follow-up years. The solid line represents the mean
399 result, while the transparent surrounding area denotes the standard deviation. (CPH 18 known risk fact

399 result, while the transparent surrounding area denotes the standard deviation. (CPH 18 known risk factors): Results
400 obtained from a CPH model using risk factors as predictors. (DCPH facial endophenotypes): Results 400 obtained from a CPH model using risk factors as predictors. (DCPH facial endophenotypes): Results obtained from a 401 DCPH model using facial endophenotypes as predictors. DCPH model using facial endophenotypes as predictors.

Discussion

 Our research underscores the promise of using facial endophenotypes, extracted from 2D facial images through AI techniques, as indicators for developing skin cancer in the future. We demonstrate that the innovative use of facial image-based predictions outperformed traditional methods relying on many known risk factors, which are normally identified based on complex patient information, including extensive questionnaires, genetic data, and clinical parameters identified during physical skin cancer screening, such as nevi count, AK, or wrinkles. Our analysis confirms the robust relationship between these facial endophenotypes and established skin cancer risk determinants. We found a notable correlation between the most predictive facial endophenotypes and certain recognized risk factors for skin cancer.

 Facial endophenotypes provide a rapid, user-friendly and explainable AI-based alternative to existing risk factors, particularly when comprehensive patient information is difficult to collect on a large scale. Furthermore, these endophenotypes might offer a more consistent prediction of skin cancer risk than relying on questionnaire data, sidestepping potential recall biases. To the best of our knowledge, our study is the first to utilize facial images and facial endophenotypes derived from these images as predictors in a skin cancer survival analysis.

Relevance to existing literature

 Previous modeling studies reported targeted skin cancer screening of high-risk populations to be a [cost-effective](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174523/)²⁴ population-based intervention to reduce skin cancer related morbidity and mortality. However, the characteristics of individuals that are considered 'high risk' [vary](https://www.valueinhealthjournal.com/article/S1098-3015(17)30003-7/pdf) across 423 studies.²⁵ Our findings provide promises that facial endophenotypes can help in narrowing the scope of high-risk individuals to optimize cost-effectiveness and improve the feasibility of targeted screening programs.

 The current literature on skin cancer risk prediction encompasses a range of prediction models with varying levels of accuracy. While some models have demonstrated promising results using relatively simpler factors, such as the number of actinic keratosis and coffee consumption $(c$ -index 0.6),²⁶ others have incorporated more extensive patient information to achieve improved accuracy. Notably, a model focused on melanoma risk achieved c-index values of [0.72](https://pubmed.ncbi.nlm.nih.gov/29538697/) for any 431 melanoma and 0.69 for invasive melanoma by incorporating seven relevant predictors.²⁷ In our study, utilizing facial endophenotypes outperformed the predictive accuracy based on known risk factors alone, yielding a c-index of 0.73, which surpasses the performance of many published models. Recent research has broadened its scope, incorporating up to 32 genetic and non-genetic 435 risk factors to remarkably enhance the accuracy of predicting future skin cancer development.⁴⁰ Nonetheless, it's vital to acknowledge that making direct comparisons between our study and prior investigations presents challenges due to variations in the populations, research methodologies employed, and, notably, the divergent primary outcomes assessed in these studies.

 Our study also revealed associations between several facial endophenotypes and known risk factors for skin cancer such as age, sex, BMI, Glogau wrinkle score, hair and skin color, history of living in a sunny country, tendency to develop sunburn, and pigment status. Age is a [well](https://onlinelibrary.wiley.com/doi/10.1111/j.1440-0960.2010.00727.x)[known](https://www.jstor.org/stable/48504055?seq=5#metadata_info_tab_contents) [risk f](https://pubmed.ncbi.nlm.nih.gov/26908057/)actor for skin cancer, $28,29,30$ with many existing prediction models relying heavily on it. Similarly, our prediction model leaned heavily on age as a discriminative variable when our analysis was restricted to known skin cancer risk factors.

 Interestingly, we were also able to corroborate previous studies that found an [inverse](https://pubmed.ncbi.nlm.nih.gov/22450736/) 446 correlation between [BMI](https://www.nature.com/articles/srep37691) and KC, meaning a higher BMI appears to reduce the risk of KC).^{31,32} 447 However, other studies focusing on melanoma observed a positive [correlation](https://www.sciencedirect.com/science/article/abs/pii/S0959804912006909) with BMI.³³ Given

 the substantial proportion of KC patients within our study cohort relative to melanoma patients, this has likely skewed our results towards an inverse correlation.

 Furthermore, we found several facial endophenotypes associated with sex to be predictive of skin cancer. Men are known to have a higher risk of developing skin cancer than women, particularly in the case of melanoma. This disparity can be attributed to a mix of genetic and behavioral factors, including men's tendency to have more sun exposure and less protection from ultraviolet (UV) radiation due to occupational and recreational activities and less care to protect from UV with cosmetics. Moreover, individuals with lighter skin tones and hair colors are more susceptible to skin cancer, including both KC and melanoma, due to their decreased melanin levels, which leaves them less protected against UV radiation. Residing in a sunny country also increases skin cancer risk due to higher cumulative exposure to UV radiation. Surprisingly, our study identified an inverse relationship between the tendency to develop sunburn and the risk of skin cancer. This counterintuitive finding could be attributed to a chance finding as this association was relatively weak. Furthermore, we were unable to correlate other known skin cancer risk factors to facial endophenotypes, such as coffee consumption and the number of nevi. This outcome is anticipated, as these risk factors would be less likely to be reflected in facial images.

Strengths and limitations

 Strengths of this study include the use of extensive population-based data from the Rotterdam Study, with over 7 years of follow-up data. Additionally, the inclusion of nationwide data on skin cancer diagnosis from the Dutch National Histopathology Registry reduces the risk of having missed skin cancer diagnoses in the studied individuals during the study follow-up period. Nevertheless, the results of our study should be understood in the context of several limitations. First, given the proof-of-concept design of our study and, as far as we are aware of, no publicly

 available datasets worldwide containing both facial images and follow-up skin cancer data, we were unable to externally validate our algorithm using an independent dataset. Second, facial images in the Rotterdam Study were collected using a highly standardized method with a dedicated camera setup, which could result in suboptimal performance when other, out-of-distribution facial photos taken under different capturing conditions (e.g., selfies taken with a front-facing smartphone camera) are used in our AI model, which can be tested in future studies. Also, a portion of right-censored samples included in our analysis had a short follow-up period, meaning they might have developed skin cancer shortly after this study's follow-up period ended, potentially impacting the prediction model negatively. Furthermore, as Rotterdam Study participants are of Dutch European ancestry and thus in majority having fair skin colour, the training and testing dataset of this study was unbalanced in terms of skin colour diversity, which may make our model less reliable when used for individuals with darker skin tones. Moreover, the study cohort is relatively old (mean age around 68) affecting the generalizability of the findings, suggesting that the impact of age may be even more dominant in the general population with a different age distribution, which should be tested in the future. Finally, we implemented an XAI approach in an attempt to shed light on the risk predictions made by our AI system. We did this by generating synthetic facial images associated with higher or lower risks of developing skin cancer. This method provides some insights, indicating that factors such as a lower BMI or increased facial erythema might be linked to a higher risk. But the inherent complexity of deep learning algorithms restricts our ability to fully understand the specific elements that boost the model's accuracy.

Conclusion

In conclusion, our research underscores the high potential of using facial images in deep-learning

 models for targeted skin cancer screening. The novel AI-driven approach we introduce here eliminates the need for collecting information via lengthy questionnaires, DNA collection, genotyping, or in-person evaluations. However, before it can be integrated into personalized screening programs, further validation within diverse population samples and less standardized setting is needed.

Acknowledgements

 The Rotterdam Study is funded by the Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (Directorate-General XII), and the Municipality of Rotterdam. G.V. Roshchupkin is supported by the ZonMw Veni grant (Veni, 549 1936320). The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.

Data sharing

 De-identified data used in this study is currently not publicly available. Researchers interested in data access should contact the corresponding author. Data requests will need to undergo ethical and legal approval by the relevant institutions.

Author contributions

- All authors made significant contributions to this scientific work and approved the final version
- of the manuscript. X.L. and T.E. were involved in the conception and design of the study,
- conducted the method development and experiments, and wrote the article. M.W and G.V.R.
- were involved in the conception and design of the study, supervised the method development and
- design of experiments, and co-wrote the article. T.N, M.K, LM.P. and E.B.W. were involved in
- the conception and design of the study, reviewed the manuscript, and provided consultation
- regarding the analysis and interpretation of the data. X.L. and T.E. have directly accessed and
- verified the underlying data reported in the manuscript.

Conflicts of interest

 The authors declare the following financial interests which may be considered potential competing interests: The Erasmus MC Department of Dermatology has received an unrestricted research grant from SkinVision B.V.

References

- 1. Zhang, W, Zeng, W, Jiang, A, et al. Global, regional and national incidence, mortality and
- disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis
- of the Global Burden of Disease Study 2019. Cancer Med. 2021; 10: 4905–4922.
- <https://doi.org/10.1002/cam4.4046>
- 2. Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and
- Projections to 2040. JAMA Dermatol. 2022;158(5):495–503.
- doi:10.1001/jamadermatol.2022.0160
- 3. Weinstock MA. Early Detection of Melanoma. JAMA. 2000;284(7):886–889.
- doi:10.1001/jama.284.7.886
- 4. Henrikson NB, Ivlev I, Blasi PR, Nguyen MB, Senger CA, Perdue LA, Lin JS. Skin Cancer
- Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023 Apr 18;329(15):1296-1307. doi: 10.1001/jama.2023.3262. PMID:
- 37071090.
- 5. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for
- Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive
- Services Task Force. JAMA. 2016 Jul 26;316(4):436-47. doi: 10.1001/jama.2016.5415. PMID:
- 27458949.
- 6. Asgari MM, Crane LA. Skin Cancer Screening: The Importance of Identifying High-risk
- Subgroups and the Need for US-Based Population Research. JAMA. 2023;329(15):1259–1260. doi:10.1001/jama.2023.3259
- 7. Fontanillas, P., Alipanahi, B., Furlotte, N.A. et al. Disease risk scores for skin cancers. Nat Commun 12, 160 (2021).<https://doi.org/10.1038/s41467-020-20246-5>
- 8. Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, Law MH, Thompson
- JF, Kanetsky PA, Begg CB, Shi Y, Kricker A, Orlow I, Sharma A, Yoo S, Leong SF, Berwick
- M, Ollila DW, Lo S. A risk prediction model for the development of subsequent primary
- melanoma in a population-based cohort. Br J Dermatol. 2020 May;182(5):1148-1157. doi:
- 10.1111/bjd.18524. Epub 2019 Nov 27. PMID: 31520533; PMCID: PMC7069770.
- 9. Wang H, Wang Y, Liang C, Li Y. Assessment of Deep Learning Using Nonimaging
- Information and Sequential Medical Records to Develop a Prediction Model for Nonmelanoma
- Skin Cancer. JAMA Dermatol. 2019;155(11):1277–1283. doi:10.1001/jamadermatol.2019.2335

 10. Fontanillas P, Alipanahi B, Furlotte NA, Johnson M, Wilson CH; 23andMe Research Team; Pitts SJ, Gentleman R, Auton A. Disease risk scores for skin cancers. Nat Commun. 2021 Jan

8;12(1):160. doi: 10.1038/s41467-020-20246-5. PMID: 33420020; PMCID: PMC7794415.

 11. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017 Feb 2;542(7639):115-118. doi: 10.1038/nature21056. Epub 2017 Jan 25. Erratum in: Nature. 2017 Jun 28;546(7660):686.

PMID: 28117445; PMCID: PMC8382232.

12. Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, Kieboom

- BCT, Klaver CCW, de Knegt RJ, Luik AI, Nijsten TEC, Peeters RP, van Rooij FJA, Stricker BH, Uitterlinden AG, Vernooij MW, Voortman T. Objectives, design and main findings until
- 2020 from the Rotterdam Study. Eur J Epidemiol. 2020 May;35(5):483-517. doi:
- 10.1007/s10654-020-00640-5. Epub 2020 May 4. PMID: 32367290; PMCID: PMC7250962.
- 13. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer
- GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the
- nationwide histopathology and cytopathology data network and archive. Cell Oncol.
- 2007;29(1):19-24. doi: 10.1155/2007/971816. PMID: 17429138; PMCID: PMC4618410.
- 14. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in
- patients with actinic keratosis: development and internal validation of a multivariable risk-
- prediction model. Br J Dermatol. 2020 Sep;183(3):495-502. doi: 10.1111/bjd.18810. Epub 2020
- Feb 26. PMID: 31856292; PMCID: PMC7496285.
- 15. Verkouteren JAC, Smedinga H, Steyerberg EW, Hofman A, Nijsten T. Predicting the Risk of a Second Basal Cell Carcinoma. J Invest Dermatol. 2015 Nov;135(11):2649-2656. doi: 10.1038/jid.2015.244. Epub 2015 Mar 3. PMID: 26121210.
- 16. Davis E. King. Dlib-ml: A Machine Learning Toolkit. Journal of Machine Learning Research 10, pp. 1755-1758, 2009
- 17. X. Hou, L. Shen, K. Sun and G. Qiu,""Deep Feature Consistent Variational Autoencoder""
- 2017 IEEE Winter Conference on Applications of Computer Vision (WACV), Santa Rosa, CA, USA, 2017, pp. 1133-1141, doi: 10.1109/WACV.2017.131.
- 18. Harrell, F.E. (2015). Cox Proportional Hazards Regression Model. In: Regression Modeling Strategies. Springer Series in Statistics. Springer, Cham. [https://doi.org/10.1007/978-3-319-](https://doi.org/10.1007/978-3-319-19425-7_20)
- [19425-7_20](https://doi.org/10.1007/978-3-319-19425-7_20)
- 19. Katzman, J.L., Shaham, U., Cloninger, A. et al. DeepSurv: personalized treatment
- recommender system using a Cox proportional hazards deep neural network. BMC Med Res
- Methodol 18, 24 (2018).<https://doi.org/10.1186/s12874-018-0482-1>
- 20. A. Cheerla and O. Gevaert. Deep learning with multimodal representation for pancancer prognosis prediction. Bioinformatics, 35(14):i446–i454, 2019.

- 21. P. Mobadersany, S. Yousefi, M. Amgad, D. A. Gut-man, J. S. Barnholtz-Sloan, J. E. V.
- Vega, D. J. Brat, and L. A. Cooper. Predicting cancer outcomes from histology and genomics
- using convolutional networks. Proceedings of the National Academy of Sciences,
- 115(13):E2970–E2979, 2018.
- 22. S. Yousefi, F. Amrollahi, M. Amgad, C. Dong, J. E. Lewis, C. Song, D. A. Gutman, S. H.
- Halani, J. E. V. Vega, D. J. Brat, et al. Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models. Scientific reports, 7(1):1–11, 2017.
- 23. Y LeCun, Y Bengio. Convolutional networks for images, speech, and time series. The
- handbook of brain theory and neural networks 3361 (10), 1995
- 24. Adamson AS, Jarmul JA, Pignone MP. Screening for Melanoma in Men: a Cost-
- Effectiveness Analysis. J Gen Intern Med. 2020 Apr;35(4):1175-1181. doi: 10.1007/s11606-019- 05443-3. Epub 2019 Nov 8. PMID: 31705474; PMCID: PMC7174523.
- 25. Gordon LG, Brynes J, Baade PD, Neale RE, Whiteman DC, Youl PH, Aitken JF, Janda M.
- Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin
- Cancer Targeting Men Older Than 50 Years. Value Health. 2017 Apr;20(4):593-601. doi:
- 10.1016/j.jval.2016.12.017. Epub 2017 Feb 15. PMID: 28408001.
- 26. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in
- patients with actinic keratosis: development and internal validation of a multivariable risk-
- prediction model. Br J Dermatol. 2020 Sep;183(3):495-502. doi: 10.1111/bjd.18810. Epub 2020
- Feb 26. PMID: 31856292; PMCID: PMC7496285.
- 27. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Webb PM, Green AC, Neale RE,
- Whiteman DC; QSkin Study. Risk Stratification for Melanoma: Models Derived and Validated
- in a Purpose-Designed Prospective Cohort. J Natl Cancer Inst. 2018 Oct 1;110(10):1075-1083.
- doi: 10.1093/jnci/djy023. PMID: 29538697.
- 28. Mar, V., Wolfe, R. and Kelly, J.W. (2011), Predicting melanoma risk for the Australian
- population. Australasian Journal of Dermatology, 52: 109-116. [https://doi.org/10.1111/j.1440-](https://doi.org/10.1111/j.1440-0960.2010.00727.x) [0960.2010.00727.x](https://doi.org/10.1111/j.1440-0960.2010.00727.x)
- 29. Quéreux, Gaelle, et al. "Development of an Individual Score for Melanoma Risk." European
- Journal of Cancer Prevention, vol. 20, no. 3, 2011, pp. 217–24. JSTOR,
- https://www.jstor.org/stable/48504055. Accessed 23 Aug. 2023.
- 30. Whiteman DC, Thompson BS, Thrift AP, Hughes MC, Muranushi C, Neale RE, Green AC,
- Olsen CM; QSkin Study. A Model to Predict the Risk of Keratinocyte Carcinomas. J Invest
- Dermatol. 2016 Jun;136(6):1247-1254. doi: 10.1016/j.jid.2016.02.008. Epub 2016 Feb 22.
- PMID: 26908057.
- 31. Pothiawala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US
- Caucasians. Cancer Causes Control. 2012 May;23(5):717-26. doi: 10.1007/s10552-012-9941-x.
- Epub 2012 Mar 27. PMID: 22450736; PMCID: PMC3704194.

- 32. Zhou, D., Wu, J. & Luo, G. Body mass index and risk of non-melanoma skin cancer:
- cumulative evidence from prospective studies. Sci Rep 6, 37691 (2016).
- <https://doi.org/10.1038/srep37691>
- 33. Theodoros N. Sergentanis, Antonios G. Antoniadis, Helen J. Gogas, Constantine N.
- Antonopoulos, Hans-Olov Adami, Anders Ekbom, Eleni Th. Petridou. Obesity and risk of
- malignant melanoma: A meta-analysis of cohort and case–control studies, European Journal of
- Cancer, Volume 49, Issue 3, 2013, Pages 642-657, [https://doi.org/10.1016/j.ejca.2012.08.028.](https://doi.org/10.1016/j.ejca.2012.08.028)
- 34. George CD, Tokez S, Hollestein L, Pardo LM, Keurentjes AJ, Wakkee M, Nijsten T.
- Longitudinal Assessment of the Prevalence of Actinic Keratosis and Extensive Risk Factor
- Evaluation: An Update from the Rotterdam Study. J Invest Dermatol. 2023 May 9:S0022-
- 202X(23)02056-0. doi: 10.1016/j.jid.2023.02.042. Epub ahead of print. PMID: 37169068.
- 35. Tokez, S., Alblas, M., Nijsten, T., Pardo, L.M. and Wakkee, M. (2020), Predicting
- keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of
- a multivariable risk-prediction model. Br J Dermatol, 183: 495-502.
- https://doi.org/10.1111/bjd.18810
- 36. Bas H.M. van der Velden, Hugo J. Kuijf, Kenneth G.A. Gilhuijs, Max A. Viergever.
- Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Medical
- Image Analysis. Volume 79, 2022, 102470, ISSN 1361-8415,
- https://doi.org/10.1016/j.media.2022.102470.
- 37. Sajid Ali, Tamer Abuhmed, Shaker El-Sappagh, Khan Muhammad, Jose M. Alonso-Moral,
- Roberto Confalonieri, Riccardo Guidotti, Javier Del Ser, Natalia Díaz-Rodríguez, Francisco
- Herrera. Explainable Artificial Intelligence (XAI): What we know and what is left to attain
- Trustworthy Artificial Intelligence. Information Fusion. Volume 99, 2023, 101805, ISSN 1566-
- 2535,<https://doi.org/10.1016/j.inffus.2023.101805>
- 38. Markus Langer, Daniel Oster, Timo Speith, Holger Hermanns, Lena Kästner, Eva Schmidt,
- Andreas Sesing, Kevin Baum. What do we want from Explainable Artificial Intelligence (XAI)?
- A stakeholder perspective on XAI and a conceptual model guiding interdisciplinary XAI
- research. Artificial Intelligence. Volume 296, 2021, 103473, ISSN 0004-3702,
- https://doi.org/10.1016/j.artint.2021.103473
- 39. Erico Tjoa, Cuntai Guan. A Survey on Explainable Artificial Intelligence (XAI): Toward
- Medical XAI. IEEE Transactions on Neural Networks and Learning Systems. Volume: 32, Issue:
- 11, November 2021. https://doi.org/10.1109/TNNLS.2020.3027314
- 40. Fontanillas, P., Alipanahi, B., Furlotte, N.A. et al. Disease risk scores for skin cancers. Nat
- Commun 12, 160 (2021). https://doi.org/10.1038/s41467-020-20246-5

Skin cancer on any location

Skin cancer on the face

Skin cancer on other regions other than the face

Higher risk

